The role of IL-6 and IL-6 blockade in COVID-19

References

• Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020 August 25;324(8):782–793.
   PubMed Web of Science ®Google Scholar
• Gautret P, Million M, Jarrot PA, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020 December;16(12):1159–1184.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Interleukin-6: from basic science to medicine–40 years in immunology. Annu Rev Immunol. 2005;23(1):1–21.
   PubMedGoogle Scholar
• Hirano T, Taga T, Yamasaki K, et al. Molecular cloning of the cDNAs for interleukin-6/B cell stimulatory factor 2 and its receptor. Ann N Y Acad Sci. 1989;557(1):167–180. discussion 178-80.
   PubMedGoogle Scholar
• Kang S, Narazaki M, Metwally H, et al. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020 May;217(5):e20190347.
   Web of Science ®Google Scholar
• Copaescu A, Smibert O, Gibson A, et al. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020 September;146(3):518–534 e1.
   PubMed Web of Science ®Google Scholar
• Gubernatorova EO, Gorshkova EA, Polinova AI, et al. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020 June;53:13–24.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, June CH, Longo DL. Cytokine Storm. N Engl J Med. 2020 December 3;383(23):2255–2273.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Farina N, Campochiaro C, et al. Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: a comprehensive review of available and emerging evidence at the peak of the pandemic. Front Pharmacol. 2020;11:598308.
   PubMed Web of Science ®Google Scholar
• Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021;2021.02.11.21249258.
   Google Scholar
• Rose-John S Interleukin-6 signalling in health and disease. F1000Res. 2020; 9.
   Google Scholar
• Su H, Lei CT, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol. 2017;8:405.
   PubMed Web of Science ®Google Scholar
• Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2003;149:1–38.
   PubMed Web of Science ®Google Scholar
• Scheller J, Grötzinger J, Rose-John S. Updating interleukin-6 classic- and trans-signaling. Signal Transduction. 2006;6(4):240–259.
   Google Scholar
• Costa-Pereira AP. Regulation of IL-6-type cytokine responses by MAPKs. Biochem Soc Trans. 2014 February;42(1):59–62.
   PubMedGoogle Scholar
• Mullberg J, Schooltink H, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993 Feb;23(2):473–480.
   PubMed Web of Science ®Google Scholar
• Lamas JR, Rodriguez-Rodriguez L, Tornero-Esteban P, et al. Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis. Cytokine. 2013 March;61(3):720–723.
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Schooltink H, Heinrich PC, et al. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol. 1992 Sep 15;149(6):2021–2027.
   PubMed Web of Science ®Google Scholar
• Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006 December;195(4):173–183.
   PubMed Web of Science ®Google Scholar
• Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994 June;300(2):281–290. 1.
   PubMed Web of Science ®Google Scholar
• Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993 August 15;82(4):1120–1126.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014 September 4;6(10):a016295.
   PubMed Web of Science ®Google Scholar
• Unver N, McAllister F. IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev. 2018 June;41:10–17.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004 May;113(9):1271–1276.
   PubMed Web of Science ®Google Scholar
• Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017 September 2;13(9):1972–1988.
   PubMed Web of Science ®Google Scholar
• Boyce EG, Rogan EL, Vyas D, et al. Sarilumab: review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis. Ann Pharmacother. 2018 Aug;52(8):780–791.
   PubMed Web of Science ®Google Scholar
• Teitsma XM, Marijnissen AK, Bijlsma JW, et al. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res Ther. 2016 September 22;18(1):211.
   PubMedGoogle Scholar
• Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002 December;46(12):3143–3150.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004 June;50(6):1761–1769.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006 September;54(9):2817–2829.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008 March 22;371(9617):987–997.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011 March;63(3):609–621.
   PubMed Web of Science ®Google Scholar
• Strand V, Michalska M, Birchwood C, et al. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. RMD Open. 2017;3(2):e000496.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Rigby W, Singer NG, et al. Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized, controlled trial. Arthritis Rheumatol. 2018 August;70(8):1200–1208.
   PubMed Web of Science ®Google Scholar
• Jones G, Wallace T, McIntosh MJ, et al. Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate- and biologic-naive or free of methotrexate for 6 months: the AMBITION study. J Rheumatol. 2017 February;44(2):142–146.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rigby WF, Van Vollenhoven RF, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017 July;76(7):1279–1284.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008 November;67(11):1516–1523.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008 October;58(10):2968–2980.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Amano K, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients–REACTION 52-week study. Rheumatology (Oxford). 2011 October;50(10):1908–1915.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 January;69(1):88–96.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, Van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550. May 4.
   PubMed Web of Science ®Google Scholar
• Finzel S, Kraus S, Figueiredo CP, et al. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis. 2019 September;78(9):1186–1191.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. Jun.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006. Mar 22.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015 March;67(3):840–848.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720–1729. Dec.
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014 January;73(1):95–100.
   PubMed Web of Science ®Google Scholar
• Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118–128. January.
   PubMed Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–1927. May 7.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. Jul 27.
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348–354. March.
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630–2640. Jun 25.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23(8):943–947. Aug.
   PubMed Web of Science ®Google Scholar
• Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7(6):R1281–8.
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005 March;52(3):818–825.
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology. 2004 April;126(4):989–996. discussion 947.
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Blade J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014 June 26;123(26):4136–4142.
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015 June;74(6):1051–1057.
   PubMed Web of Science ®Google Scholar
• Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016;18(1):225. Oct 6.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017 Feb;69(2):277–290.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840–847. May.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Thorne C, Karpouzas G, et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017;76(12):2001–2008. Dec.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Bingham CO 3rd, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017;389(10075):1206–1217. Mar 25.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Schiff MH, Wang Q, et al. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann Rheum Dis. 2018 May;77(5):658–666.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Strand V, Merrill JT, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017;76(3):534–542. Mar.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Van Vollenhoven RF, Aranow C, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 2016;68(9):2174–2183. Sep.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–1615. Sep.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Yamanaka H, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15–23.
   PubMed Web of Science ®Google Scholar
• Nasonov E, Fatenejad S, Korneva E, et al. Safety and efficacy of Olokizumab in a Phase III trial of patients with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate – CREDO1 study [abstract]. Arthritis Rheumatol. 2019;71(suppl 10). Accessed 2021 Feb 21. https://acrabstracts.org/abstract/safety-and-efficacy-of-olokizumab-in-a-phase-iii-trial-of-patients-with-moderately-to-severely-active-rheumatoid-arthritis-inadequately-controlled-by-methotrexate-credo1-study/
   Google Scholar
• Mease PJ, Gottlieb AB, Berman A, et al. The efficacy and safety of Clazakizumab, an anti-interleukin-6 monoclonal antibody, in a Phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol. 2016;68(9):2163–2173. Sep.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–2632. Oct 15.
   PubMed Web of Science ®Google Scholar
• Van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug;15(9):966–974.
   PubMed Web of Science ®Google Scholar
• Van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020 Dec 8;4(23):6039–6050.
   PubMed Web of Science ®Google Scholar
• Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019 Jul;186(2):269–273.
   PubMed Web of Science ®Google Scholar
• Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020 May;39(5):405–407.
   PubMed Web of Science ®Google Scholar
• Polidoro RB, Hagan RS, De Santis Santiago R, et al. Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Front Immunol. 2020;11:1626.
   PubMed Web of Science ®Google Scholar
• Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020 July;146(1):128–136 e4.
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020 Jun;26(6):842–844.
   PubMed Web of Science ®Google Scholar
• Bost P, Giladi A, Liu Y, et al. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell. 2020 June 25;181(7):1475–1488 e12.
   PubMed Web of Science ®Google Scholar
• Karnowski A, Chevrier S, Belz GT, et al. B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J Exp Med. 2012 October 22;209(11):2049–2064.
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 April 30;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Vecchie A, Bonaventura A, Toldo S, et al. IL-18 and infections: is there a role for targeted therapies? J Cell Physiol. 2021 Mar;236(3):1638–1657.
   PubMed Web of Science ®Google Scholar
• Bonaventura A, Vecchie A, Wang TS, et al. Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies. Front Immunol. 2020;11:1625.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020 May 1;130(5):2620–2629.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846–848.
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Stevens H, Peter K. The emerging threat of (Micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020 Jul 31;127(4):571–587.
   PubMed Web of Science ®Google Scholar
• Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 March;19(3):141–154.
   PubMed Web of Science ®Google Scholar
• Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021 February;590(7847):635–641.
   PubMed Web of Science ®Google Scholar
• Patra T, Meyer K, Geerling L, et al. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog. 2020 December;16(12):e1009128.
   PubMed Web of Science ®Google Scholar
• Toldo S, Bussani R, Nuzzi V, et al. Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm Res. 2021 January;70(1):7–10.
   PubMed Web of Science ®Google Scholar
• Rodrigues TS, De Sa KSG, Ishimoto AY, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218(3). Mar 1. DOI: 10.1084/jem.20201707.
   PubMed Web of Science ®Google Scholar
• Pandolfi L, Fossali T, Frangipane V, et al. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome. BMC Pulm Med. 2020 November 16;20(1):301.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Renia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 June;20(6):363–374.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao B, Qu Y, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically Ill patients with coronavirus disease 2019. Clin Infect Dis. 2020 November 5;71(8):1937–1942.
   PubMed Web of Science ®Google Scholar
• Tisoncik JR, Korth MJ, Simmons CP, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012 March;76(1):16–32.
   PubMed Web of Science ®Google Scholar
• Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020 March 27;5(1):33.
   PubMed Web of Science ®Google Scholar
• Abbasifard M, Khorramdelazad H. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: a brief look at potential therapeutic tactics. Life Sci. 2020 Sep 15;257:118097.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020 June 10;27(6):992–1000 e3.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhou X, Yan S, et al. Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU. Clin Chim Acta. 2020 November;510:47–53.
   PubMed Web of Science ®Google Scholar
• Levi M, Van Der Poll T, Ten Cate H, et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest. 1997 January;27(1):3–9.
   PubMed Web of Science ®Google Scholar
• Levi M, Van Der Poll T, Van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005 October;15(7):254–259.
   PubMed Web of Science ®Google Scholar
• Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis. 2021 February;51(2):313–329.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Potere N, Candeloro M, et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. Eur J Intern Med. 2021 January;83:34–38.
   PubMed Web of Science ®Google Scholar
• Canzano P, Brambilla M, Porro B, et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl Sci. 2021 March;6(3):202–218.
   PubMedGoogle Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 April;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417–1418.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 March 28;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020 May;55:102763.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 July 28;71(15):762–768.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang J, Yang Y, et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020 July 7;12(7):e12421.
   PubMed Web of Science ®Google Scholar
• Ryabkova VA, Churilov LP, Shoenfeld Y. Influenza infection, SARS, MERS and COVID-19: cytokine storm - the common denominator and the lessons to be learned. Clin Immunol. 2021 February;223:108652.
   PubMed Web of Science ®Google Scholar
• Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018 Dec;18(12):773–789.
   PubMed Web of Science ®Google Scholar
• McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020 September 15;202(6):812–821.
   PubMed Web of Science ®Google Scholar
• Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020 May 1;130(5):2202–2205.
   PubMed Web of Science ®Google Scholar
• Zhu J, Pang J, Ji P, et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol. 2021 January;93(1):35–37.
   PubMed Web of Science ®Google Scholar
• Udomsinprasert W, Jittikoon J, Sangroongruangsri S, et al. Circulating levels of interleukin-6 and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis. J Clin Immunol. 2021 January;41(1):11–22.
   PubMed Web of Science ®Google Scholar
• Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020 November;30(6):1–9.
   PubMed Web of Science ®Google Scholar
• Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Eur Cytokine Netw. 2020 June 1;31(2):44–49.
   PubMed Web of Science ®Google Scholar
• Ji P, Zhu J, Zhong Z, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine (Baltimore). 2020 November 20;99(47):e23315.
   PubMed Web of Science ®Google Scholar
• Laguna-Goya R, Utrero-Rico A, Talayero P, et al. IL-6-based mortality risk model for hospitalized patients with COVID-19. J Allergy Clin Immunol. 2020 October;146(4):799–807 e9.
   PubMed Web of Science ®Google Scholar
• Said EA, Al-Reesi I, Al-Shizawi N, et al. Defining IL-6 levels in healthy individuals: a meta-analysis. J Med Virol. 2021;93(6):3915–3924. Nov 6.
   PubMed Web of Science ®Google Scholar
• Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020 December;8(12):1233–1244.
   PubMed Web of Science ®Google Scholar
• Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020 June;16(6):335–345.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970–10975.
   PubMed Web of Science ®Google Scholar
• Potere N, Di Nisio M, Rizzo G, et al. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. Int J Infect Dis. 2020 November;100:421–424.
   PubMed Web of Science ®Google Scholar
• Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020 June;76:31–35.
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 June;76:43–49.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 August;2(8):e474–e484.
   PubMedGoogle Scholar
• Potere N, Di Nisio M, Cibelli D, et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study. Ann Rheum Dis. 2021 February;80(2):1–2.
   PubMed Web of Science ®Google Scholar
• Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020 October;2(10):e603–e612.
   PubMedGoogle Scholar
• Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian centre study on tocilizumab versus standard of care. J Clin Virol. 2020 August;129:104444.
   PubMed Web of Science ®Google Scholar
• Albertini L, Soletchnik M, Razurel A, et al. Observational study on off-label use of tocilizumab in patients with severe COVID-19. Eur J Hosp Pharm. 2021 January;28(1):22–27.
   PubMedGoogle Scholar
• Masia M, Fernandez-Gonzalez M, Padilla S, et al. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study. EBioMedicine. 2020 October;60:102999.
   PubMed Web of Science ®Google Scholar
• Zhao M, Lu J, Tang Y, et al. Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. Eur J Clin Pharmacol. 2021 March;77(3):311–319.
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2021 February;27(2):215–227.
   PubMed Web of Science ®Google Scholar
• Kow CS, Hasan SS. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2021 2 Feb;1-6. DOI: 10.1007/s00228-021-03087-z.
   Web of Science ®Google Scholar
• Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021 January 1;181(1):24–31.
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020 December 10;383(24):2333–2344.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv. 2020;2020.08.27.20183442.
   Google Scholar
• Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021 January 1;181(1):32–40.
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021 January 7;384(1):20–30.
   PubMed Web of Science ®Google Scholar
• Investigators R-C, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Feb 25;NEJMoa2100433. DOI: 10.1056/NEJMoa2100433.
   Web of Science ®Google Scholar
• Tocilizumab reduces deaths in patients hospitalised with COVID-19. https://www.recoverytrial.net/news/tocilizumab-reduces-deaths-in-patients-hospitalised-with-covid-19. Last accessed 2021 Feb 13
   Google Scholar
• Benucci M, Giannasi G, Cecchini P, et al. COVID-19 pneumonia treated with Sarilumab: a clinical series of eight patients. J Med Virol. 2020 November;92(11):2368–2370.
   PubMed Web of Science ®Google Scholar
• Gremese E, Cingolani A, Bosello SL, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020 October;27:100553.
   PubMedGoogle Scholar
• Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020 October;79(10):1277–1285.
   PubMed Web of Science ®Google Scholar
• Sinha P, Mostaghim A, Bielick CG, et al. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. Int J Infect Dis. 2020 October;99:28–33.
   PubMed Web of Science ®Google Scholar
• Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. https://www.sanofi.com/en/media-room/press-releases/2020/2020-09-01-07-00-00 ( n.d.) Last accessed 2021 February 19
   Google Scholar
• Regeneron Pharmaceuticals, Inc. (2020). Regeneron and Sanofi provide update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients. https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3 Last accessed 2021 February 19
   Google Scholar
• Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report. medRxiv. 2021;2021.01.07.21249390.
   PubMedGoogle Scholar
• Gritti G, Raimondi F, Ripamonti D, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv. 2020;2020.04.01.20048561.
   Google Scholar
• Maes B, Bosteels C, De Leeuw E, et al. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020 June 3;21(1):468.
   PubMedGoogle Scholar
• Marchetti C, Mould K, Tengesdal IW, et al. Targeting of the NLRP3 inflammasome for early COVID-19. bioRxiv. 2021;2021.02.24.432734.
   Google Scholar
• Amigues I, Pearlman AH, Patel A, et al. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol. 2020 December;16(12):1185–1204.
   PubMed Web of Science ®Google Scholar
• Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020 June 6;395(10239):1763–1770.
   PubMed Web of Science ®Google Scholar
• Chamorro-de-vega E, Rodriguez-Gonzalez CG, Manrique-Rodriguez S, et al. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain. Expert Rev Clin Pharmacol. 2021 February;14(2):249–260.
   PubMed Web of Science ®Google Scholar
• Castelnovo L, Tamburello A, Lurati A, et al. Anti-IL6 treatment of serious COVID-19 disease: a monocentric retrospective experience. Medicine (Baltimore). 2021 January 8;100(1):e23582.
   PubMed Web of Science ®Google Scholar
• Sarhan RM, Madney YM, Abou Warda AE, et al. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab. Int J Clin Pract. 2021;6:e14079.
   Google Scholar
• Pomponio G, Ferrarini A, Bonifazi M, et al. Tocilizumab in COVID-19 interstitial pneumonia. J Intern Med. 2021. Jan 29. DOI: 10.1111/joim.13231
   PubMed Web of Science ®Google Scholar
• Veiga VC, Prats J, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 January;20(372):n84.
   Google Scholar
• Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. https://www.roche.com/investors/updates/inv-update-2020-07-29.htm. Last accessed 2021 February 15th.
   Google Scholar
• Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020 June;95:304–307.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 March 28;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Sinha P, Matthay MA, Calfee CS. Is a “Cytokine Storm” relevant to COVID-19? JAMA Intern Med. 2020 September 1;180(9):1152–1154.
   PubMed Web of Science ®Google Scholar
• Kox M, Waalders NJB, Kooistra EJ, et al. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA. 2020;324(15):1565. Sep 3.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Larcher A, Tomelleri A, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 April;3(4):e253–e261.
   PubMedGoogle Scholar